Biopharmaceutical company Pfizer announced today that a Phase 2/3 trial revealed that the COVID-19 vaccine was safe resulted in a “robust” antibody response in children ages 5 to 11, according to CNN and their company press release.
Pfizer said in the release that it will submit to the US Food and Drug Administration for emergency use authorization in the near future. FDA officials have said that when the data is submitted, the drug agency could authorize a vaccine for this younger group of children in the next few weeks, according to the article. The trial had nearly 2,700 participants ranging between 5 and 11 years old who used a two-dose regimen of the vaccine administered 21 days apart, according to the article. This trial used a 10-microgram dose — much smaller than the 30-microgram dose that is contained
Click to read the full article @New Pittsburgh Courier